Market Cap (In USD)
299.69 Million
Revenue (In USD)
36.52 Million
Net Income (In USD)
-101.74 Million
Avg. Volume
919.23 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.7-13.005
- PE
- -
- EPS
- -
- Beta Value
- 0.879
- ISIN
- US87583X1090
- CUSIP
- 87583X109
- CIK
- 1819133
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Barbara L. Weber M.D.
- Employee Count
- -
- Website
- https://www.tangotx.com
- Ipo Date
- 2020-09-03
- Details
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
More Stocks
-
EQH
-
NAUBF
-
GIPIF
-
ATRAtrem S.A.
ATR
-
DXCMDexCom, Inc.
DXCM
-
DELTACORPDelta Corp Limited
DELTACORP
-
9078S Line Co.,Ltd.
9078
-
TELIATelia Company AB (publ)
TELIA